Loading organizations...
§ Private Profile · Fremont, CA, USA
Miikana Therapeutics is a technology company.
Miikana Therapeutics develops targeted medicines for cancer treatment, leveraging internal discovery and in-licensed pre-clinical assets. Its oncology pipeline focuses on novel small molecules designed to precisely interfere with cancer cell proliferation pathways. This approach, exemplified by candidates like MKC-1, an orally-active cell cycle inhibitor, aims for effective and specific therapeutic options.
Miikana Therapeutics was established in 2002 by co-founder and CEO Dinesh Patel, and founder Dr. Tak W. Mak. Dr. Mak, a distinguished expert from The Campbell Family Institute for Breast Cancer Research, provided the foundational scientific insight into developing highly targeted oncology treatments, forming a clinically driven biopharmaceutical entity.
Miikana Therapeutics primarily serves cancer patients, offering potentially life-altering therapeutic solutions. The company’s vision is to advance a portfolio of innovative, targeted oncology drugs that significantly improve patient outcomes. It strives to bring forward novel mechanisms of action that precisely attack cancer cells, transforming cancer treatment.
Miikana Therapeutics has raised $7.0M across 2 funding rounds.
Miikana Therapeutics has raised $7.0M in total across 2 funding rounds.
Miikana Therapeutics has raised $7.0M across 2 funding rounds. Most recently, it raised $3.0M Series A in October 2004.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2004 | $3M Series A | — | 5AM Ventures | Announced |
| Sep 1, 2003 | $4M Series A | — | 5AM Ventures | Announced |
The premise of your query is incorrect: Miikana Therapeutics is not a technology company—it is a biopharmaceutical company focused on discovering and developing targeted cancer medicines.
Miikana Therapeutics is a clinically driven biopharmaceutical company discovering and developing targeted medicines for cancer treatment[1][2]. Rather than building software or technology products, Miikana develops pharmaceutical drugs through internal research programs and by in-licensing pre-clinical and early clinical oncology candidates[1]. The company serves cancer patients and the broader oncology market by leveraging molecular disease mechanism insights and extensive anti-cancer clinical development expertise to advance its drug pipeline[1].
Miikana was established in 2002 by members of the cancer research team from the University Health Network's Ontario Cancer Institute and the former Amgen Research Institute in Toronto[1]. The founding team includes notable figures such as Dr. Tak Mak, Dinesh V. Patel (President and Chief Operating Officer), S. Gail Eckhardt (Senior Advisor for Oncology Drug Development), Mark R. Bray (Director of Research), and Colleen M. Paige (Vice President of Finance)[1]. The company operates with joint research facilities in the Bay Area, California and Toronto, Canada, combining medicinal chemistry expertise with a management team of high-profile scientists and clinical drug developers[1].
Miikana represents a focused approach within oncology drug development, operating at the intersection of academic cancer research and commercial pharmaceutical development. By combining internal discovery capabilities with in-licensing strategies, the company positions itself to accelerate drug development timelines—a critical advantage in the competitive oncology space where patient need is urgent and development costs are substantial.
Miikana Therapeutics has raised $7.0M in total across 2 funding rounds.
Miikana Therapeutics's investors include 5AM Ventures.